Drug Profile: Mebeverine Hydrochloride

Authors

  • S. Shanmugam Department of Pharmaceutics, Adhiparasakthi College of Pharmacy, Melmaruvathur, Tamil Nadu, India
  • T. Ayyappan Department of Pharmaceutics, Adhiparasakthi College of Pharmacy, Melmaruvathur, Tamil Nadu, India
  • T. Vetrichelvan Department of Pharmaceutics, Adhiparasakthi College of Pharmacy, Melmaruvathur, Tamil Nadu

DOI:

https://doi.org/10.37591/tdd.v3i3.295

Abstract

Irritable bowel syndrome (IBS) is the most prevalent functional gastrointestinal disorder noted in the general population worldwide. Its chronic nature, signs and symptoms which vary periodically from mild to severe have many negative effects on the quality of life for the sufferer; therefore, the appropriate treatment of these patients is highly important. Patients should be informed by their doctors that the nature of the disease is benign, and educated on how to deal with and control symptoms of the disease. Mebeverine is used to treat a number of problems. It is a direct relaxant of gut (intestinal) muscle, and is sometimes known as an antispasmodic drug. It is used to relax the muscles of the intestine and to treat symptoms of irritable bowel syndrome and related conditions.

 

Keywords: Gastrointestinal disorder, Mebeverine, Antispasmodic drug, Bowel syndrome

Cite this Article

Shanmugam S, Ayyappan T, Vetrichelvan T. Drug Profile: Mebeverine Hydrochloride. Trends in Drug Delivery. 2016; 3(3): 20–22p

Downloads

Published

2019-02-22

Issue

Vol. 3 No. 3 (2016)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.